Duality Biotherapeutics, Inc.

Duality Biotherapeutics, Inc.

HHKEX:9606
93.25
HKD
-4.05
(-4.16%)
16.41BMarket Cap
Mar 23Next Earn
Duality Biotherapeutics, Inc.
HKEX:9606
(Hong Kong Exchange)

Recent

price

93.25

P/E

ratio

- -

div

yld

- -

ROIC.AI

2022
2023
2024
2025
TTM
CNY
0.02
21.48
23.34
20.71
- -
Revenue per Share
-4.65
-4.3
-12.63
-29.02
- -
Basic EPS, GAAP
-3.87
9.38
3.06
2.02
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
Dividend per Share
-9.25
-13.51
-24.31
27.14
16.02
Book Value per Share
-9.86
-14.16
-24.86
27.1
15.99
Tangible Book Value per Share
83
83
83
89
90
Basic Weighted Avg Shares
2
1,787
1,941
1,852
- -
Sales/Revenue/Turnover
-23,107.31
41.45
-10.48
-24.57
- -
Operating Margin (%)
2
5
8
12
- -
Depreciation Expense
-387
-358
-1,050
-2,595
- -
Net Income, GAAP
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-24,193.12
-20.01
-54.11
-140.13
- -
Profit Margin (%)
-826
-1,227
-1,962
2,782
1,722
Working Capital
2
2
2
4
136
LT Debt
-769
-1,124
-2,022
2,427
1,451
Total Equity
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
65
146
243
LT Borrowings
- -
- -
134
LT Finance Leases
3
4
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
88
89
91
Market Capitalization
19,009
23,959
14,195

Working Capital

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
4,090
3,834
3,464
Cash, Cash Equivalents & STI
3,701
3,374
3,036
Accounts Receivable, Net
288
278
148
Inventories
- -
- -
- -
Total Current Liabilities
865
1,052
1,742
Payables & Accruals
- -
- -
- -
ST Debt
65
146
243
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-220.02%
Free Cash Flow
- -
- -
-28.96%
Net Income, GAAP
- -
- -
147.02%
Sales/Revenue/Turnover
- -
- -
-4.61%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1,941
2025
- -
- -
1,852
2026
- -
- -
- -

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-12.63
2025
- -
- -
-29.02
2026
- -
- -
- -

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Business
Duality Biotherapeutics Inc. functions as a biotechnology firm in the clinical development phase. It is dedicated to the creation of advanced antibody-drug conjugates, including bispecific and immune-modulating varieties, targeting both oncological and autoimmune conditions. The company originated in 2019 and maintains its principal offices in Shanghai, China. Duality Biotherapeutics leverages proprietary platforms like DITAC to advance a robust pipeline of over a dozen therapeutic candidates. Its portfolio includes lead candidates such as DB-1303 for HER2-expressing cancers, DB-1305 for solid tumors, DB-1310 for lung cancer, DB-1311 for various solid tumors, and DB-2304 for autoimmune diseases like lupus, many of which have received Fast Track designation. The company has established significant global collaborations with pharmaceutical leaders, including BioNTech, GSK, and Avenzo Therapeutics, for the development and commercialization of its innovative treatments across international markets. Duality Biotherapeutics listed on the Hong Kong Stock Exchange in 2025, furthering its commitment to bringing novel therapies to patients worldwide.